Antibody Immune Response RNA Scientist 
The Pharma Data
AUGUST 16, 2021
Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.
Drug Discovery World
JANUARY 12, 2024
The top stories: Excitement over new antibiotics that can kill drug-resistant bacteria A novel antibiotic class targeting a major global pathogen and threat to human health has been discovered by scientists from Roche and Harvard University (Cambridge, MA, US).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 26, 2022
Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The lecture is one of a series of named lectures, organised by the LMB and given by eminent scientists from around the world. .
The Pharma Data
MARCH 8, 2022
Proteins of SARS-CoV-2 can alter viral ribonucleic acids in a way, that they become indistinguishable from endogenous RNA. Camouflage protects virus from immune system. For example, viral RNAs are masked by the addition of a methyl group. “A robust, early type I IFN production is key to clearing SARS-CoV-2 infection.
The Pharma Data
JANUARY 22, 2021
As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.
The Pharma Data
JULY 6, 2021
But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. ” In the same time period, mRNA vaccines were being deployed and immune responses to those vaccines were being studied.
Drug Discovery World
JUNE 27, 2023
Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. CD8+ T cells have been the focal point of anti-cancer therapies.
Expert insights. Personalized for you.
52 
Let's personalize your content